2016 ASCO Annual Meeting Abstract 8001: Lenalidomide (LEN) Maintenance (MNTC) After High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma (MM): A Meta-Analysis (MA) of Overall Survival (OS)
This large MA demonstrates that LEN MNTC significantly prolonged OS vs CTL post ASCT, including in pts who achieved CR, demonstrating benefit in pts in all response categories.
ASCO
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant